Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Isabella Henderson, Nisali A Gunawardane, Ruben I Kuzniecky

Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1 Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and sudden unexpected death in epilepsy (SUDEP).2 Early identification of DRE is critical to enable timely exploration […]

Angelo Antonini, AD/PD 2022: α-Synuclein seeding activity in gastrointestinal biopsies of Parkinson’s disease patients

10 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 5th 2022

Gastrointestinal dysfunctions represent one of the main non-motor symptoms in Parksinon’s disease (PD). Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses a study that investigated α-Synuclein seeding activity in stomach-duodenum biopsies of PD patients by real-time quaking induced conversion (RT-QuIC) assay. The results suggest a deeper investigation in detection of α-Synuclein seeding activity in the early stages of PD in gastrointestinal biopsies via RT-QuIC as an early biomarker of disease.

The abstract entitled: ‘Detection of α-Synuclein Seeding Activity by RT-QUIC Assay in Gastrointestinal Biopsies of Patients with Advanced Parkinson’s Disease’ was presented at the International Conference of Alzheimer’s and Parkinson’s diseases and related neurological disorders (AD/PD), 13-15 October 2021.

Questions:

  1. What unmet needs exist in the detection of the prodromal phase of Parkinson’s disease (PD)? (0:20)
  2. What evidence is there to support the hypothesis that α-Synuclein seeding activity occurs in the gastrointestinal tract in PD? (3:32)
  3. What were the aims and methodology,  study findings? (5:49)
  4. What will be the next stages of this research? (8:13)

Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, Biopharma, Britannia, Ever Pharma, UCB, Jazz Pharmaceuticals, Kyowa Kirin, Theravance, Roche, Zambon; receives grant/research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals,  Horizon 2020 – Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation, and Movement Disorders Society.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of AD/PD 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup